What's Happening?
The World Health Organization (WHO) has approved Coartem Baby, the first malaria drug specifically designed for infants. This new treatment, which comes in sweet cherry-flavored tablets that can be dissolved
into liquids, including breast milk, aims to address the treatment gap for infants as small as 2kg. Previously, infants with malaria were treated with formulations intended for older children, which increased the risk of dosing errors, side effects, and toxicity. The approval is expected to help reduce the high malaria-related mortality rates among young children in Africa, where up to 18% of children under six months are infected with malaria. The drug, developed by Novartis and the Medicines for Malaria Venture (MMV), contains two antimalarial drugs, artemether and lumefantrine.
Why It's Important?
The approval of Coartem Baby is a significant public health milestone, particularly for sub-Saharan Africa, where malaria is a leading cause of death among young children. By providing a safe and effective treatment option for infants, the drug has the potential to significantly reduce mortality rates. The WHO's prequalification of the drug means it meets international standards of quality, safety, and efficacy, allowing for public-sector procurement in countries with high malaria rates. This development challenges the historical misconception that young babies cannot be infected with malaria due to immunity passed on by their mothers, highlighting the need for targeted treatments for this vulnerable group.
What's Next?
Following its approval, Coartem Baby has already been introduced in Ghana, with plans for wider distribution in malaria-endemic regions. Novartis has committed to making the treatment available on a largely not-for-profit basis. The introduction of this drug is part of a broader strategy to combat malaria, which includes new vaccines, diagnostic tests, and next-generation mosquito nets. The success of Coartem Baby could pave the way for further innovations in malaria treatment and prevention, potentially leading to a significant reduction in the disease's impact on young children.
